Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
102 institutional managers report a position in Cardiff Oncology, Inc. worth $24.5M between them, filed on form 13F for the quarter ending 2026-06-30. 14 of them hold 80% of it, the largest being Laurion Capital Management LP at 16.41%.
77 more managers in the register
14 managers hold 80% of the $24.5M institutional base. The other 88 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
Cardiff Oncology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 1.34 · opened flat. High/low 1.48 at 12:15 pm ET, 1.33 at 3:30 pm ET.
CRDF (Cardiff Oncology, Inc.) has 3 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.04%, in healthcare.
via Laurion Capital Management LP, Pfizer Inc, Marshall Wace LLP · 16.41% of CRDF, 14.36% of PYXS
via Pfizer Inc, GSA Capital Partners LLP · 12.28% of CRDF, 11.14% of SPRO
via Pfizer Inc, GSA Capital Partners LLP, Marshall Wace LLP +1 more · 12.28% of CRDF, 9.24% of CRBU
via Laurion Capital Management LP · 16.41% of CRDF, 10.86% of AARD
via Pfizer Inc, HRT Financial LLC, Marshall Wace LLP · 12.28% of CRDF, 7.19% of ALLO
via Franklin Resources Inc, Marshall Wace LLP, Qube Research & Technologies Ltd · 6.39% of CRDF, 15.47% of BSAC
Managers holding a meaningful stake in CRDF also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.